NCT05465941: PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer |
|
|
| Recruiting | 2 | 43 | US | Biopsy, Bx, BIOPSY_TYPE, Pegylated SN-38 Conjugate PLX038, Pegylated SN-38 PLX038, PLX 038, PLX-038, PLX038, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, computerized axial tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT SCAN, tomography, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection | Mayo Clinic, National Cancer Institute (NCI) | Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8 | 05/27 | 12/31 | | |
NCT04209595: PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers |
|
|
| Active, not recruiting | 1/2 | 10 | US | PLX038, PEGylated SN38, Rucaparib, Rubraca, Ondansetron, Zofran | National Cancer Institute (NCI) | Small Cell Lung Cancer, Extra-Pulmonary Small Cell Carcinomas | 08/21 | 12/24 | | |
